Recent Press Releases

Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal

Culinary Expert Visits Los Angeles on November 9 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management

Salix Pharmaceuticals Reports 3Q2014 Results

3Q14 Total Net Product Revenue Increases 49% Year-over-Year to $355 million 3Q14 EBITDA Increases 63% Year-over-Year to $161 million 3Q14 XIFAXAN® 550 Prescriptions Increase 23%...

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors PITTSBURGH, Nov. 7, 2014 /PRNewswire/ -- Mylan Inc. (MYL)...

FRESENIUS KABI AND RUSSIAN PARTNERS TERMINATE JOINT VENTURE AGREEMENT

FRESENIUS KABI AND RUSSIAN PARTNERS TERMINATE JOINT VENTURE AGREEMENT November 06, 2014-Bad Homburg v.d.H. -- Fresenius Kabi and its partners Sistema JSFC and Zenitco Finance Management LLC have...

Amgen To Present At The Credit Suisse Annual Healthcare Conference

THOUSAND OAKS, Calif., Nov.

Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 6, 2014

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers<

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic...

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company - Accelerates Perrigo's stated strategy to expand internationally and leverage its...

ASTRAZENECA TO DIVEST MYALEPT TO AEGERION

ASTRAZENECA TO DIVEST MYALEPT TO AEGERION 6 November 2014 AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™...

Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps

Extensive review and analysis of research data completed Final stage to focus on planned in-field use studies Best Management Practices and Certification Program adopted FDA approval of...

Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015

Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 DUBLIN, Nov. 5, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced...

Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19

Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 - Increases Second Half Non-GAAP EPS Forecast to $6.60-$6.70 - - 158% Increase in Third...

Endo Reports Third Quarter Financial Results

Endo Reports Third Quarter Financial Results Total quarterly revenues of $764 million, reported diluted (GAAP) loss per share of $1.64 and adjusted diluted EPS of $1.15. - Strong financial results...

MERCK: EXECUTIVE BOARD MEMBER OSCHMANN ELECTED PRESIDENT OF IFPMA

MERCK: EXECUTIVE BOARD MEMBER OSCHMANN ELECTED PRESIDENT OF IFPMA Presidency at IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) under overarching theme of...

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update – Strong LINZESS® (linaclotide) demand: total prescription growth of 22% and sequential U.S. net product sales growth of...

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

Study Failed to Meet Secondary Endpoint of Overall Survival

THOUSAND OAKS, Calif., Nov.

Abbott to Present at Credit Suisse 2014 Healthcare Conference

ABBOTT PARK, Ill., Nov.

Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 4, 2014

Regeneron Reports Third Quarter 2014 Financial and Operating Results

TARRYTOWN, N.Y., Nov. 4, 2014 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2014 and provided an update on development programs....